KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema

KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.

Full Story →